Rodman & Renshaw Cuts Rexahn Pharma (RNN) to Market Perform
RNN Hot Sheet
Rating Summary:1 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Rodman & Renshaw's Elemer Piros downgraded shares of Rexahn Pharma (NYSE: RNN) from Market Outperform to Market Perform.
The stock is up nearly 17 percent at last check amid European approval to conduct a first-in-human trial for its RX-3117.
For an analyst ratings summary and ratings history on Rexahn Pharma click here. For more ratings news on Rexahn Pharma click here.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
The stock is up nearly 17 percent at last check amid European approval to conduct a first-in-human trial for its RX-3117.
For an analyst ratings summary and ratings history on Rexahn Pharma click here. For more ratings news on Rexahn Pharma click here.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
- Caris & Co. Downgrades Viacom (VIA) to Above Average
- Goldman Sachs Downgrades Raytheon (RTN) to Sell; Risk To Back-End Loaded 2012
Create E-mail Alert Related Categories
DowngradesRelated Entities
Rodman & RenshawSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
